Project Grant K99CA297011
Award Date
3/1/25
Completion Date
2/28/27
Dollars Obligated
$155K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This $284,201.82 Project Grant from the National Cancer Institute, a division of the Department of Health and Human Services, will fund research into malignant cell engagement in immune circuits of human colorectal cancer. The Broad Institute, Inc. will utilize single cell RNA sequencing data from over 700,000 malignant, immune, and stromal cells from colorectal cancer patients to test the hypothesis that malignant cells expressing interferon-stimulated genes acutely promote anti-tumor immunity,...
The federal Project Grant award R37CA292807, totaling $640,583, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The primary goal of this 5-year project is to enhance the efficacy of immunotherapy against metastatic colorectal cancer (MCRC) by activating the PPARD-CPT1A axis in CD8+ T cells. The research aims to delineate the mechanisms by which PPARD activation boosts the anti-tumor activity of CD8+ T cells, elucidate the role of...
This National Cancer Institute (CFDA 93.396 Cancer Biology Research) Project Grant award of $560,297 to the Icahn School of Medicine at Mount Sinai supports research to functionally characterize oncofetal stem cells (ONFSCs) in colorectal cancer (CRC). The key objectives are to: Generate phenotypic transcriptional reporters to track the dynamics of LGR5+ cancer stem cells (CSCs) and ONFSCs, and use these to dissect the functional interplay between these stem cell populations. Employ a multi-omic...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $546,625.00 to the University of Pittsburgh to develop and test a nanocarrier platform for codelivery of small interfering RNA (siRNA) targeting the IRHOM1 gene and a chemotherapeutic prodrug conjugate (CPT-SAHA) for the treatment of metastatic colorectal cancer. The key objectives are to: 1) characterize the biophysical and biological properties of the nanocarrier...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $205,700.00 to the Sloan-Kettering Institute for Cancer Research in New York to support research aimed at addressing the problem of rapid resistance to targeted therapies in colorectal cancer. The key objectives are to: 1) evaluate how intrinsic tumor features modulate the development of targeted therapy resistance, and 2) test a novel combination approach of DNA repair inhibition...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by Duke University to develop novel immunotherapies using optimized tumor cell-penetrating antibodies. The primary objective is to translate these tumor cell-penetrating antibodies into the clinic to effectively combat aggressive human cancers driven by mutational hotspots, potentially overcoming resistance to small molecule inhibitors. Specifically, the researchers...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides funding to support the computational research and platform development activities of a laboratory-based research specialist at the Cleveland Clinic Lerner College of Medicine. The key products and services delivered under this $212,567 award, spanning from September 2024 to August 2029, include: Computational analysis of cancer patient-derived next-generation...
This $181,640 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research led by a clinical scientist at The University of Texas MD Anderson Cancer Center. The primary objectives are to: Expand on the role of liquid biopsy biomarkers, specifically circulating tumor DNA (ctDNA) and extravesicle RNA (evRNA), to generate novel combination immunotherapy trials for colorectal and anal cancers. This includes analyzing samples from...
This $693,880 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports the development of a novel cancer immunotherapy approach using engineered CD4+ T cells. The goal is to create CD4+ T cells that can target the tumor microenvironment and overcome resistance to current immune checkpoint inhibitor therapies. Key elements include: Identifying key molecules and immune cell targets of the engineered CD4+ T cells in preclinical cancer...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $406,611 to the University of Texas Health Science Center at Houston (UTHealth) to investigate the role and therapeutic targeting of the GPR56 receptor in colorectal cancer. The key objectives are to: 1) characterize how GPR56 signaling impacts colorectal cancer stem cell plasticity and metastasis using patient-derived organoid models; 2) develop and evaluate highly potent...